Background/Objectives: Damage Control Resuscitation (DCR) is a critical strategy in the management of severe trauma, focusing on the optimisation of the patient’s physiological condition. This study reviews current DCR strategies, emphasizing the mitigation of the “diamond of death”—hypothermia, acidosis, coagulopathy, and hypocalcemia—while addressing complex disturbances like respiratory distress syndrome (ARDS) and (acute kidney injury) AKI in high-ISS (Injury Severity Score) patients. Methods: A systematic review of 59 contemporary sources was conducted, encompassing clinical trials (e.g., CRASH-2), military-to-civilian protocol translations, and guidelines from the C and European Resuscitation Council. The analysis focused on pre-hospital interventions, in-hospital transfusion protocols, and the impact of transport logistics on survival. Results: Evidence highlights that aggressive crystalloid resuscitation (over 5 L) significantly increases mortality, favoring balanced blood component therapy (1:1:1 ratio) or Whole Blood guided by viscoelastic testing like rotational thromboelastometry (ROTEM) or thromboelastography (TEG). Pre-hospital success is driven by rapid hemorrhage control via tourniquets, early administration of Tranexamic Acid (TXA), no aggressive crystalloids, permissive hypotension, proactive calcium supplementation is recommended in early care. Furthermore, the integration of Helicopter Emergency Medical Services (HEMS) is independently associated with improved survival in multi-organ trauma by reducing time to definitive care and facilitating “en-route” damage control. Conclusions: The evolution of rescue strategies focused on mitigating the effects of the diamond of death, combined with the implementation of permissive hypotension and optimized HEMS logistics, constitutes the foundation of a modern model aimed at minimizing mortality in multi-organ trauma.

Current scientific research demonstrates that cutaneous melanoma and mucosal melanoma are two distinct disease entities, considering the complexities of their diagnosis and treatment. Mucosal melanoma is characterized by a significantly poorer prognosis than cutaneous melanoma, with a 5-year overall survival (OS) rate of less than 20%. Surgical resection remains the gold standard of management; however, there is currently a paradigm shift away from routine, complication-prone completion lymph node dissection toward selective surveillance using serial ultrasound. This approach significantly improves patients’ quality of life without negatively impacting OS. Due to anatomical constraints (e.g., oral cavity, paranasal sinuses), narrow resection margins are supplemented with radiotherapy. Although this effectively reduces the risk of local recurrence, it does not prolong OS due to rapid distant metastasis, which occurs in approximately half of the patients within the first year. In systemic treatment, the standard of care involves dual immune checkpoint blockade (nivolumab plus ipilimumab) as well as BRAF/MEK and tyrosine kinase inhibitors (imatinib, nilotinib). The efficacy of immunotherapy in mucosal melanoma is significantly lower compared to that in cutaneous melanoma. The application of nivolumab plus ipilimumab yields slightly better outcomes than anti-PD-1 monotherapy; however, the proportion of patients achieving a durable response to treatment and the long-term survival rates remain highly unsatisfactory. The insufficient efficacy of current treatment paradigms highlights a critical need for the development of novel strategies. These include the broader application of Mohs micrographic surgery and the implementation of experimental therapies currently under investigation, such as anti-angiogenic treatments, oncolytic viruses, vaccines, adoptive T-cell therapies (e.g. CAR-T), bispecific antibodies (e.g. brenetafusp), and gut microbiome modulation.

Background: Obesity is fundamentally characterized by low-grade chronic inflammation (LGCI), driven by hypertrophic adipocytes and macrophage infiltration that release pro-inflammatory cytokines (e.g., TNF-α, IL-6). Vitamin D, recognized as a potent immunomodulator, holds significant potential in mitigating this inflammatory cascade. This review evaluates the impact of vitamin D supplementation on the pro-inflammatory cytokine profile and metabolic parameters in patients with obesity and metabolic syndrome. Methods: A comprehensive literature review was conducted using PubMed and Google Scholar databases. The analysis encompassed 31 scientific articles, including recent meta-analyses and randomized controlled trials (RCTs), focusing on the interplay between vitamin D, systemic inflammation, and obesity-related metabolic disturbances. Results: Current evidence indicates that vitamin D supplementation significantly reduces systemic inflammatory markers (IL-6, hs-CRP, TNF-α) and improves insulin resistance indices (HOMA-IR) and lipid profiles. However, supplementation alone does not induce significant reductions in body mass index (BMI) or total adipose tissue volume. Furthermore, owing to vitamin D sequestration in adipose tissue and volumetric dilution, patients with obesity require personalized, high-dose regimens (often ≥4,000 IU/day) to achieve optimal serum 25(OH)D levels (30–50 ng/mL) necessary for clinical immunomodulation. Conclusions: While vitamin D is not a standalone weight-loss intervention, it serves as a crucial adjunctive therapy for modulating the LGCI associated with obesity. Current data do not support extrapolating these anti-inflammatory effects to a definitive reduction in cardiometabolic risk. However, achieving optimal serum levels requires personalized dosing to address altered pharmacokinetics, alongside essential lifestyle modifications, including diet and exercise.

Attention-Deficit/Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder traditionally linked to monoaminergic dysregulation within the brain’s reward circuitry. Recent evidence points to the potential role of the gut-brain axis (GBA), a bidirectional communication network linking the central nervous system with the enteric microbiota. This narrative review explores the proposed associations between intestinal dysbiosis and ADHD symptoms, as well as the potential for GBA-targeted therapeutic interventions. Research suggests that individuals with ADHD may exhibit distinct microbial profiles, characterized by an increased abundance of genera such as Bifidobacterium and Bacteroides , and a depletion of anti-inflammatory taxa like Faecalibacterium . These shifts are hypothesized to contribute to “leaky gut” syndrome, potentially triggering systemic inflammation and neuroinflammation that could disrupt neural circuits responsible for executive function. Furthermore, experimental models indicate that gut microbes may modulate the availability of dopamine precursors, indirectly influencing reward processing. Preliminary clinical data suggest that “psychobiotics,” synbiotics, and targeted micronutrient supplementation (e.g., iron, zinc, and magnesium in cases of confirmed deficiencies) might serve as supportive interventions and potentially improve quality of life. While standard pharmacotherapy remains the primary treatment, GBA-focused strategies are being investigated as adjunctive therapies, offering a promising yet preliminary avenue for personalized management. Integrating these interventions may help manage common comorbidities across the lifespan, though further robust clinical trials are required.